Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LV232 Serotonin Transporter Occupancy PET Study
NCT06476509Phase 1Completed
- Sponsor
- Vigonvita Life Sciences
- Start
- May 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of LV232 in major depressive disorder (MDD) (4 arms), sponsored by Vigonvita Life Sciences. Primary endpoint: Serotonin Transporters occupancy. Started May 2024; status: completed.
02
Drugs
LV232
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06476509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06476509.